In a move that could help drastically slow the advancement of Alzheimer's disease (AD), the US Food and Drug Administration (FDA) has cleared C2N Diagnostics' PrecivityAD2 blood test for patients as young as 40 who have shown some potential cognitive symptoms of the condition.

The U.S. Food and Drug Administration (FDA) has cleared PrecivityAD2 for marketing, an innovative blood-based diagnostic test for Alzheimer's disease